Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Organisation › Details

CRISPR Therapeutics AG (Nasdaq: CRSP)

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D., who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. *

 

Period Start 2013-01-01 established
  Group CRISPR Therapeutics (Group)
Product Industry CRISPR gene editing technology
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Prasad, Raju (CRISPR Therapeutics 202303– CFO before William Blair)
     
Region Region Basel BS
  Country Switzerland
  Street 36 Aeschenvorstadt
  City 4051 Basel BS
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
  Currency USD
  Annual sales 289,590,000 (revenue, collaboration, consolidated (2019) 2019-12-31)
  Profit 66,858,000 (2019-12-31)
  Cash 943,800,000 (2019-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-02-15

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top